CONTEXT: Low testosterone levels have been associated with outcomes that reduce survival in men. OBJECTIVE: Our objective was to perform a systematic review and meta-analysis of published studies to evaluate the association between endogenous testosterone and mortality. DATA SOURCES: Data sources included MEDLINE (1966 to December 2010), EMBASE (1988 to December 2010), and reference lists. STUDY SELECTION: Eligible studies were published English-language observational studies of men that reported the association between endogenous testosterone and all-cause or cardiovascular disease (CVD) mortality. A two-stage process was used for study selection. 1) Working independently and in duplicate, reviewers screened a subset (10%) of abstracts. Results indicated 96% agreement, and thereafter, abstract screening was conducted in singlicate. 2) All full-text publications were reviewed independently and in duplicate for eligibility. DATA EXTRACTION: Reviewers working independently and in duplicate determined methodological quality of studies and extracted descriptive, quality, and outcome data. DATA SYNTHESIS: Of 820 studies identified, 21 were included in the systematic review, and 12 were eligible for meta-analysis [n = 11 studies of all-cause mortality (16,184 subjects); n = 7 studies of CVD mortality (11,831 subjects)]. Subject mean age and testosterone level were 61 yr and 487 ng/dl, respectively, and mean follow-up time was 9.7 yr. Between-study heterogeneity was observed among studies of all-cause (P < .001) and CVD mortality (P = 0.06), limiting the ability to provide valid summary estimates. Heterogeneity in all-cause mortality (higher relative risks) was observed in studies that included older subjects (P = 0.020), reported lower testosterone levels (P = 0.018), followed subjects for a shorter time period (P = 0.010), and sampled blood throughout the day (P = 0.030). CONCLUSION: Low endogenous testosterone levels are associated with increased risk of all-cause and CVD death in community-based studies of men, but considerable between-study heterogeneity, which was related to study and subject characteristics, suggests that effects are driven by differences between cohorts (e.g. in underlying health status).
CONTEXT: Low testosterone levels have been associated with outcomes that reduce survival in men. OBJECTIVE: Our objective was to perform a systematic review and meta-analysis of published studies to evaluate the association between endogenous testosterone and mortality. DATA SOURCES: Data sources included MEDLINE (1966 to December 2010), EMBASE (1988 to December 2010), and reference lists. STUDY SELECTION: Eligible studies were published English-language observational studies of men that reported the association between endogenous testosterone and all-cause or cardiovascular disease (CVD) mortality. A two-stage process was used for study selection. 1) Working independently and in duplicate, reviewers screened a subset (10%) of abstracts. Results indicated 96% agreement, and thereafter, abstract screening was conducted in singlicate. 2) All full-text publications were reviewed independently and in duplicate for eligibility. DATA EXTRACTION: Reviewers working independently and in duplicate determined methodological quality of studies and extracted descriptive, quality, and outcome data. DATA SYNTHESIS: Of 820 studies identified, 21 were included in the systematic review, and 12 were eligible for meta-analysis [n = 11 studies of all-cause mortality (16,184 subjects); n = 7 studies of CVD mortality (11,831 subjects)]. Subject mean age and testosterone level were 61 yr and 487 ng/dl, respectively, and mean follow-up time was 9.7 yr. Between-study heterogeneity was observed among studies of all-cause (P < .001) and CVD mortality (P = 0.06), limiting the ability to provide valid summary estimates. Heterogeneity in all-cause mortality (higher relative risks) was observed in studies that included older subjects (P = 0.020), reported lower testosterone levels (P = 0.018), followed subjects for a shorter time period (P = 0.010), and sampled blood throughout the day (P = 0.030). CONCLUSION: Low endogenous testosterone levels are associated with increased risk of all-cause and CVD death in community-based studies of men, but considerable between-study heterogeneity, which was related to study and subject characteristics, suggests that effects are driven by differences between cohorts (e.g. in underlying health status).
Authors: Varant Kupelian; Stephanie T Page; Andre B Araujo; Thomas G Travison; William J Bremner; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2006-01-04 Impact factor: 5.958
Authors: Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day Journal: Circulation Date: 2007-11-26 Impact factor: 29.690
Authors: Carol A Derby; Sophia Zilber; Don Brambilla; Knashawn H Morales; John B McKinlay Journal: Clin Endocrinol (Oxf) Date: 2006-07 Impact factor: 3.478
Authors: Ewa A Jankowska; Bartosz Biel; Jacek Majda; Alicja Szklarska; Monika Lopuszanska; Marek Medras; Stefan D Anker; Waldemar Banasiak; Philip A Poole-Wilson; Piotr Ponikowski Journal: Circulation Date: 2006-10-09 Impact factor: 29.690
Authors: Majon Muller; Diederick E Grobbee; Isolde den Tonkelaar; Steven W J Lamberts; Yvonne T van der Schouw Journal: J Clin Endocrinol Metab Date: 2005-02-01 Impact factor: 5.958
Authors: Andre B Araujo; Varant Kupelian; Stephanie T Page; David J Handelsman; William J Bremner; John B McKinlay Journal: Arch Intern Med Date: 2007-06-25
Authors: Annabelle Rodriguez; Denis C Muller; E Jeffrey Metter; Marcello Maggio; S Mitchell Harman; Marc R Blackman; Reubin Andres Journal: J Clin Endocrinol Metab Date: 2007-06-26 Impact factor: 5.958
Authors: K K Tsilidis; S Rohrmann; K A McGlynn; S J Nyante; D S Lopez; G Bradwin; M Feinleib; C E Joshu; N Kanarek; W G Nelson; E Selvin; E A Platz Journal: Andrology Date: 2013-09-30 Impact factor: 3.842
Authors: Annewieke W van den Beld; Jean-Marc Kaufman; M Carola Zillikens; Steven W J Lamberts; Josephine M Egan; Aart J van der Lely Journal: Lancet Diabetes Endocrinol Date: 2018-07-17 Impact factor: 32.069
Authors: Robin Haring; Zhaoyang Teng; Vanessa Xanthakis; Andrea Coviello; Lisa Sullivan; Shalender Bhasin; Joanne M Murabito; Henri Wallaschofski; Ramachandran S Vasan Journal: Clin Endocrinol (Oxf) Date: 2013-04 Impact factor: 3.478